Read Trending Stories
- » Consumer Biz Recap: Talbots Shares CRASH HARD, Time Warner Eyes Sports Website
- » Global Investors Opt for Safety as Spain Remains Scary
- » Do Spain's Red Flags Scream Caution?
- » Consumer Biz Recap: Toyota Needs New Markets, Wal-Mart's Express Update
- » Yahoo: You'll Forget Chrome and Safari When You See This
Today's Trending Stocks
Click a Company to Research Now:
- Bank of America (BAC)
- Apple . (AAPL)
- Facebook (FB)
- AT&T (T)
- Nokia (NOK)
- Delcath Systems (DCTH)
- Mentor Graphics Corp (MENT)
- Complete Genomics (GNOM)
Spectrum Pharmaceuticals (NASDAQ:SPPI) announces positive results. Zevalin is improving outcomes of high-risk lymphomas according to a paper published by Cancer. SPPI shares were up premarket.
Columbia Labs (NASDAQ:CBRX) is down over 50% after trading was suspended following a negative vote on the company’s Prochieve drug candidate from the Food and Drug Administration. Partner, Watson Pharmaceuticals (NYSE:WPI) is little changed after falling slightly on Friday as well. Columbia Labs’ rival K-V (KV.A) is up again after a 9.3% gain on Friday.
Earnings Report: Bristol-Myers Squibb Co. Fourth Quarter Earnings Sneak Peek.
Boston Scientific (NYSE:BSX) announces a favorable ruling for a patent infringement case filed against BSX by Johnson & Johnson (NYSE:JNJ).
Alexa Pharmaceuticals (NASDAQ:ALXA) shares are hit hard after the Food and Drug Administration says it needs an additional three months to complete Adassuve’s, a schizophrenic and bipoloar disorder drug, application review.
Cel-Sci Corporation (AMEX:CVM) shares explode after phase III clinical trials for Multikine were launched in dozens of hospitals located in eight countries on three continents. Mulitkine is a cancer drug.
Don’t Miss: EA at Outperform Rating, Teradyne at Buy Rating, Biogen an Overweight.
Get Your FREE Special Report: 4 Things You Must Know About the US Economy Now!
Do You Want More Profits? Wall St. Cheat Sheet Premium newsletter subscribers have been crushing the markets with winning stock picks.
Click here now for your FREE trial to our acclaimed flagship newsletter:
